Talimogene laherparepvec	granulocyte-macrophage colony-stimulating factor (GM-CSF)	The incidence of any grade adverse events	20592	20655	The incidence of any grade AE was similar in the two study arms
Talimogene laherparepvec	granulocyte-macrophage colony-stimulating factor (GM-CSF)	overall response rate (ORR)	1317	1527	ORR was also higher in the talimogene laherparepvec arm (40.5% versus 2.3%; P<0.0001), and 27 patients in the talimogene laherparepvec arm had a complete response, compared with none in GM-CSF-treated patients.
Talimogene laherparepvec	granulocyte-macrophage colony-stimulating factor (GM-CSF)	The incidence of any grade adverse events	20592	20740	The incidence of any grade AE was similar in the two study arms: 98.8% versus 93.4% for talimogene laherparepvec and GM-CSF, respectively (Table 4).
Talimogene laherparepvec	granulocyte-macrophage colony-stimulating factor (GM-CSF)	durable response rate (DRR)	1159	1316	Among 249 evaluated patients with stage IIIBâ€“IVM1a melanoma, DRR was higher with talimogene laherparepvec compared with GM-CSF (25.2% versus 1.2%; P<0.0001).
Talimogene laherparepvec	granulocyte-macrophage colony-stimulating factor (GM-CSF)	overall response rate (ORR)	17194	17294	ORR was also higher in the talimogene laherparepvec arm (40.5% versus 2.3%, respectively; P<0.0001).
